Seroatlas · Human Serome Atlas

PGLYRP2

N-acetylmuramoyl-L-alanine amidase

Also known as: PGLYRPL, PGRP-L, PGRP2_HUMAN, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q96PD5
Gene
PGLYRP2
Ensembl
ENSG00000161031
Chromosome
19
Canonical length
576 aa
Protein class
Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins
Subcellular location
Cell Junctions
Secretome location
Secreted to blood

OverviewNCBI Gene

This gene encodes a peptidoglycan recognition protein, which belongs to the N-acetylmuramoyl-L-alanine amidase 2 family. This protein hydrolyzes the link between N-acetylmuramoyl residues and L-amino acid residues in bacterial cell wall glycopeptides, and thus may play a scavenger role by digesting biologically active peptidoglycan into biologically inactive fragments. [provided by RefSeq, Sep 2011]

Canonical amino-acid sequenceUniProt

576 residues, UniProt reviewed canonical sequence.

>Q96PD5|PGLYRP2
     1  MAQGVLWILL GLLLWSDPGT ASLPLLMDSV IQALAELEQK VPAAKTRHTA SAWLMSAPNS
    61  GPHNRLYHFL LGAWSLNATE LDPCPLSPEL LGLTKEVARH DVREGKEYGV VLAPDGSTVA
   121  VEPLLAGLEA GLQGRRVINL PLDSMAAPWE TGDTFPDVVA IAPDVRATSS PGLRDGSPDV
   181  TTADIGANTP DATKGCPDVQ ASLPDAKAKS PPTMVDSLLA VTLAGNLGLT FLRGSQTQSH
   241  PDLGTEGCWD QLSAPRTFTL LDPKASLLTM AFLNGALDGV ILGDYLSRTP EPRPSLSHLL
   301  SQYYGAGVAR DPGFRSNFRR QNGAALTSAS ILAQQVWGTL VLLQRLEPVH LQLQCMSQEQ
   361  LAQVAANATK EFTEAFLGCP AIHPRCRWGA APYRGRPKLL QLPLGFLYVH HTYVPAPPCT
   421  DFTRCAANMR SMQRYHQDTQ GWGDIGYSFV VGSDGYVYEG RGWHWVGAHT LGHNSRGFGV
   481  AIVGNYTAAL PTEAALRTVR DTLPSCAVRA GLLRPDYALL GHRQLVRTDC PGDALFDLLR
   541  TWPHFTATVK PRPARSVSKR SRREPPPRTL PATDLQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PGLYRP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
242 nTPM

Expression across tissuesHPA

Tissue

  • liver: 242 nTPM
  • testis: 6.6 nTPM
  • breast: 1.5 nTPM
  • prostate: 0.4 nTPM
  • thymus: 0.3 nTPM
  • urinary bladder: 0.3 nTPM

Single-cell type

  • hepatocytes: 199 nCPM
  • plasma cells: 18 nCPM
  • epididymal efferent duct absorptive cells: 16 nCPM
  • hepatic stellate cells: 13 nCPM
  • breast hormone-responsive cells: 9.2 nCPM
  • late spermatids: 7.2 nCPM

Immune cell

  • non-classical monocyte: 5.1 nTPM
  • basophil: 3.4 nTPM
  • naive CD8 T-cell: 2.3 nTPM
  • naive CD4 T-cell: 2.2 nTPM
  • intermediate monocyte: 1.7 nTPM
  • gdT-cell: 1.6 nTPM

Brain region

  • cerebral cortex: 0.2 nTPM
  • hippocampal formation: 0.1 nTPM
  • medulla oblongata: 0.1 nTPM
  • pons: 0.1 nTPM
  • amygdala: 0 nTPM
  • basal ganglia: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.27
gnomAD pLI
0
gnomAD missense Z
1.07
DepMap mean gene effect
0.04
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PGLYRP2 as an antibody target. Whether an autoantibody or antibody against PGLYRP2 could matter depends on whether native PGLYRP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PGLYRP2 is annotated as secreted, so native PGLYRP2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label PGLYRP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PGLYRP2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...